The sepsis syndrome has been revealed to be incredibly complex, involving many mediators that we just now are starting to appreciate. Future clinical trials of new sepsis-related therapeutic products may need to consider other endpoints in addition to mortality. Also, better identification of the subset of patients likely to benefit from these products is necessary, as are rapid diagnostic assays for endotoxin, tumor necrosis factor, and various cytokines.
|Original language||English (US)|
|Number of pages||2|
|Journal||Complications in Surgery|
|State||Published - Jan 1 1994|
ASJC Scopus subject areas